- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07483450
En studie for å evaluere effekt, sikkerhet, farmakokinetikk og farmakodynamikk for Ocrelizumab hos deltakere med tilbakevendende multippel sklerose og primær progressiv multippel sklerose
Et multicenter, åpent merket, enarmsstudie for å evaluere effekt, sikkerhet, farmakokinetikk og farmakodynamikk av ocrelizumab hos kinesiske pasienter med tilbakevendende multippel sklerose og primær progressiv multippel sklerose
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Beijing, Kina, 100034
- Peking University First Hospital
-
Beijing, Kina, 100032
- Peking Union Medical College Hospital
-
Beijing, Kina, 100730
- Beijing Hospital of Ministry of Health
-
Changsha, Kina, 410008
- Xiangya Hospital Central South University
-
Chengdu, Kina, 610041
- West China Hospital of Sichuan University
-
Chongqing, Kina, 400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou, Kina, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, Kina, 510630
- The Third Affiliated Hospital of Sun Yat-Sen University
-
Hangzhou, Kina, 310003
- The First Affiliated Hospital of College of Medicine, Zhejiang University
-
Hohhot, Kina, 010011
- Inner Mongolia Autonomous Region People's Hospital
-
Lanzhou, Kina, 730030
- Lanzhou University Second Hospital
-
Shenyang, Kina, DUMMY_VALUE
- The First Hospital of China Medical University
-
Shijiazhuang, Kina, 050000
- The Second Hospital of Hebei Medical University
-
Taiyuan, Kina, 030000
- 1st Affiliated Hospital of Shanxi Medical University
-
Wuhan, Kina, 430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Ürümqi, Kina, 830000
- Xinjiang People Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330209
- The First Affiliated Hospital of Nanchang University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
- EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
- Documented MRI of brain with abnormalities consistent with MS before screening
Exclusion Criteria:
- Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
- History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
- Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
- History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- Inability to complete an MRI scan or contraindication to Gd administration
- Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
- Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- Known history of human immunodeficiency virus (HIV) infection
- Lack of peripheral venous access
- Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
- Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: RMS Cohort
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Andre navn:
|
|
Eksperimentell: PPMS Cohort
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
RMS-kohorten: Årlig protokoll-definert tilbakefallsrate
Tidsramme: Opptil omtrent 1,6 år
|
Opptil omtrent 1,6 år
|
|
PPMS-kohort: B-celle-nivåer i blod
Tidsramme: Opp til uke 48
|
Opp til uke 48
|
|
PPMS-kohort: Prosentandel av deltakere som oppnår nivåer av B-celler med klassedifferensiering 19 (CD19+) på <10 celler/mikroliter (μL) ved uke 48
Tidsramme: Etter 48 uker
|
Etter 48 uker
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
RMS-kohorten: Prosentandel av deltakere som ikke har tegn på sykdomsaktivitet (NEDA3) i løpet av en 48-ukers periode
Tidsramme: Opptil uke 48
|
Opptil uke 48
|
|
|
RMS-kohort: Prosentandel av deltakere uten tilbakefall etter uke 48
Tidsramme: Opp til uke 48
|
Opp til uke 48
|
|
|
RMS-kohort: Prosentandel av deltakere som har NEDA3 i en 24-ukers periode
Tidsramme: Opp til uke 24
|
Opp til uke 24
|
|
|
RMS-kohort: Totalt antall T1 Gadolinium (Gd)-forsterkende lesjoner oppdaget ved Magnetisk Resonans Avbildning (MRI) av hjernen
Tidsramme: Opp til uke 48
|
Opp til uke 48
|
|
|
RMS-kohorten: Totalt antall nye eller forstørrede T2-hyperintense lesjoner påvist ved hjerne-MRI
Tidsramme: Frem til uke 48
|
Frem til uke 48
|
|
|
RMS- og PPMS-kohortene: Endring fra baseline til uke 48 i konsentrasjonen av serum neurofilament lett kjede (Nfl)
Tidsramme: Baseline opp til uke 48
|
Baseline opp til uke 48
|
|
|
RMS- og PPMS-kohorter: Serumkonsentrasjon av Ocrelizumab
Tidsramme: Opptil uke 48
|
Opptil uke 48
|
|
|
RMS-kohort: B-celnivå i blod
Tidsramme: Opp til uke 48
|
Opp til uke 48
|
|
|
RMS-kohort: Prosentandel av deltakere som oppnår CD19+ B-celle-nivåer på <10 celler/μL ved uke 48
Tidsramme: Etter 48 uker
|
Etter 48 uker
|
|
|
PPMS-kohort: Totalt antall T1 Gd-forsterkende lesjoner påvist ved hjerneskanning (MRI) uke 24 og uke 48
Tidsramme: Uke 24 og Uke 48
|
Uke 24 og Uke 48
|
|
|
PPMS-kohort: Totalt antall nye eller forstørrede T2-hyperintense lesjoner detektert ved hjerne-MRI ved uke 24 og uke 48
Tidsramme: Uke 24 og uke 48
|
Uke 24 og uke 48
|
|
|
RMS og PPMS kohortene: Antall deltakere med bivirkninger (AEs)
Tidsramme: Opptil omtrent 1,8 år
|
Opptil omtrent 1,8 år
|
|
|
RMS- og PPMS-kohorter: Endring fra baseline i T-cellenivå
Tidsramme: Opptil omtrent 1,8 år
|
Opptil omtrent 1,8 år
|
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
Tidsramme: Baseline up to Week 48
|
EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
Tidsramme: Baseline up to Week 48
|
The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
Tidsramme: Baseline up to Week 48
|
The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
Tidsramme: Baseline, Week 48
|
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. |
Baseline, Week 48
|
|
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsramme: Up to approximately 1.8 years
|
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior. |
Up to approximately 1.8 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i nervesystemet
- Patologiske prosesser
- Kronisk sykdom
- Sykdomsattributter
- Autoimmune sykdommer
- Sykdommer i immunsystemet
- Demyeliniserende autoimmune sykdommer, CNS
- Autoimmune sykdommer i nervesystemet
- Demyeliniserende sykdommer
- Patologiske tilstander, tegn og symptomer
- Multippel sklerose
- Multippel sklerose, kronisk progressiv
- Ocrelizumab
Andre studie-ID-numre
- YN44938
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .